Institution
University of Arkansas for Medical Sciences
Education•Little Rock, Arkansas, United States•
About: University of Arkansas for Medical Sciences is a education organization based out in Little Rock, Arkansas, United States. It is known for research contribution in the topics: Population & Health care. The organization has 14077 authors who have published 26012 publications receiving 973592 citations. The organization is also known as: UAMS.
Topics: Population, Health care, Medicine, Poison control, Multiple myeloma
Papers published on a yearly basis
Papers
More filters
••
TL;DR: There is wide variation in mental health morbidity and use of mental health care across racial and ethnic groups in the United States, and these results can help to focus efforts aimed at understanding the underlying causes of the differences.
Abstract: Objectives:We compared rates of mental health problems and use of mental health care across multiple racial and ethnic groups using secondary data from a large, nationally representative survey.Methods:We pooled cross-sectional data from the 2001–2003 National Surveys on Drug Use and Health. Our sam
210 citations
••
TL;DR: Nonrandom, unbalanced whole-arm translocations of 1q are reported in the cytogenetic evolution of patients with aggressive MM and may be associated with highly decondensed pericentromeric heterochromatin, which may permit recombination and formation of unstable translocation of chromosome 1q.
210 citations
••
TL;DR: It is suggested that women with a more diverse gut microbiome exhibit an elevated urinary ratio of hydroxylated estrogen metabolites to parent estrogen, which has been predictive of postmenopausal breast cancer risk in previous studies.
Abstract: Context: The gut microbiota may influence the risk of breast cancer through effects on endogenous estrogens. Objective: The objective of the study was to investigate whether urinary estrogens and estrogen metabolites are associated with the diversity and composition of the fecal microbiome. Design and Setting: This was a cross-sectional study among women enrolled in Kaiser Permanente of Colorado. Participants: A total of 60 women drawn from a random sample of healthy postmenopausal women (aged 55–69 y), without current or recent use of antibiotics or hormone therapy and no history of cancer or gastrointestinal disease participated in the study. Outcome Measures and Methods: Creatinine-standardized urinary estrogens (estrone and estradiol) and 13 hydroxylated estrogen metabolites were measured in spot urines by liquid chromatography-tandem mass spectrometry. The fecal microbiome was assessed using pyrosequencing of 16S rRNA amplicons. General linear models were used to test for associations of diversity an...
210 citations
••
University of Salamanca1, Harvard University2, Mayo Clinic3, University of Turin4, University of Texas MD Anderson Cancer Center5, Carolinas Healthcare System6, University of Arkansas for Medical Sciences7, Indiana University – Purdue University Indianapolis8, Cornell University9, University of Würzburg10, National and Kapodistrian University of Athens11, University of Toulouse12, University of Gothenburg13, Lund University14, Vrije Universiteit Brussel15, Roswell Park Cancer Institute16, Queen Mary University of London17, University of New Brunswick18, VU University Medical Center19, Tufts University20, National University of Singapore21, Erasmus University Rotterdam22
TL;DR: This work reviews the biological rationale for the use of the most important new agents for treating Multiple myeloma, and discusses data from already approved and active agents (including second- and third-generation proteasome inhibitors, immunomodulatory agents and alkylators).
Abstract: Treatment in medical oncology is gradually shifting from the use of nonspecific chemotherapeutic agents toward an era of novel targeted therapy in which drugs and their combinations target specific aspects of the biology of tumor cells. Multiple myeloma (MM) has become one of the best examples in this regard, reflected in the identification of new pathogenic mechanisms, together with the development of novel drugs that are being explored from the preclinical setting to the early phases of clinical development. We review the biological rationale for the use of the most important new agents for treating MM and summarize their clinical activity in an increasingly busy field. First, we discuss data from already approved and active agents (including second- and third-generation proteasome inhibitors (PIs), immunomodulatory agents and alkylators). Next, we focus on agents with novel mechanisms of action, such as monoclonal antibodies (MoAbs), cell cycle-specific drugs, deacetylase inhibitors, agents acting on the unfolded protein response, signaling transduction pathway inhibitors and kinase inhibitors. Among this plethora of new agents or mechanisms, some are specially promising: anti-CD38 MoAb, such as daratumumab, are the first antibodies with clinical activity as single agents in MM. Moreover, the kinesin spindle protein inhibitor Arry-520 is effective in monotherapy as well as in combination with dexamethasone in heavily pretreated patients. Immunotherapy against MM is also being explored, and probably the most attractive example of this approach is the combination of the anti-CS1 MoAb elotuzumab with lenalidomide and dexamethasone, which has produced exciting results in the relapsed/refractory setting.
210 citations
••
TL;DR: The March of Dimes Scientific Advisory Committee created this prioritized research agenda, aimed at garnering serious attention and expanding resources to make major inroads into the prevention of PTB, targeting six major, overlapping categories: epidemiology, genetics, disparities, inflammation, biologic stress, and clinical trials.
210 citations
Authors
Showing all 14187 results
Name | H-index | Papers | Citations |
---|---|---|---|
Hagop M. Kantarjian | 204 | 3708 | 210208 |
Yusuke Nakamura | 179 | 2076 | 160313 |
Kenneth C. Anderson | 178 | 1138 | 126072 |
David R. Williams | 178 | 2034 | 138789 |
Yang Yang | 171 | 2644 | 153049 |
John E. Morley | 154 | 1377 | 97021 |
Jeffrey L. Cummings | 148 | 833 | 116067 |
Hugh A. Sampson | 147 | 816 | 76492 |
Michael J. Keating | 140 | 1169 | 76353 |
Kristine Yaffe | 136 | 794 | 72250 |
Nancy J. Cox | 135 | 778 | 109195 |
Stephen W. Scherer | 135 | 685 | 85752 |
Nikhil C. Munshi | 134 | 906 | 67349 |
Siamon Gordon | 131 | 420 | 77948 |
Jian-Guo Bian | 128 | 1219 | 80964 |